Table 3.

Adjusted effects of Na level on 90-day adverse outcomes (death or LT) in cirrhosis patients (n = 2774)

	Number of 90-day adverse outcomes (percentage)	OR, 95% CI, p value Model I	OR, 95% CI, p value Model II	OR, 95% CI, p value Model III	OR, 95% CI, p value Model IV
Na (continuous)	626 (22.57)	0.90 (0.88,0.91) < 0.001	0.90 (0.88,0.91) < 0.001	0.91 (0.89,0.92) < 0.001	0.95 (0.93,0.96) < 0.001
Na-categorical
(Na 135–145 mmol/L)	336 (16.9)	1	1	1	1
(Na > 145 mmol/L)	11 (19)	1.15 (0.59,2.24)0.677	1.17 (0.60,2.29)0.641	0.92 (0.47,1.83)0.822	1.20 (0.58,2.50)0.623
(Na 120–135 mmol/L)	266 (38.1)	3.02 (2.50,3.67) < 0.001	3.02 (2.49,3.66) < 0.001	2.64 (2.16,3.23) < 0.001	1.78 (1.42,2.23) < 0.001
(Na ≤ 120 mmol/L)	13 (48.1)	4.57 (2.13,9.81) < 0.001	4.64 (2.16,9.96) < 0.001	4.01 (1.84,8.74) < 0.001	2.13 (0.86,5.24)0.100
p value for trend*		< 0.001	< 0.001	< 0.001	< 0.001
Na (continuous 5 mmol/L decrease)		0.58 (0.53,0.63) < 0.001	0.58 (0.53,0.63) < 0.001	0.6 (0.56,0.67) < 0.001	0.75 (0.68,0.83) < 0.001
Na (continuous 10 mmol/L decrease)		0.34 (0.28,0.40) < 0.001	0.34 (0.28,0.40) < 0.001	0.3 (0.31,0.45) < 0.001	0.57 (0.47,0.69) < 0.001

Model I Un-adjusted;

Model II Adjusted for age, sex;

Model III Adjusted for age, sex, HE, ascites, infection;

Model IV Adjusted for age, sex, HE, ascites, infection, TBIL, INR, CR;

CI confidence interval

^*Test for trend based on variables containing median value for each group